Other languages Fennec Pharmaceuticals Inc. Toronto S.E.

Equities

FRX

CA31447P1009

Market Closed - Toronto S.E. Other stock markets 01:29:59 18/07/2024 am IST			5-day change	1st Jan Change
9.1 ^CAD	-0.55%		+12.62%	-39.97%

02/07	MT Newswires Weekend Stocks To Watch: BCE; Bitfarms; Fennec; GreenPower; Hut 8; Restaurant Brands; Sigma Lithium; Solaris	MT
01/07	Fennec Pharmaceuticals Chief Operating Officer Adrian Haigh Steps Down	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

MT Newswires Weekend Stocks To Watch: BCE; Bitfarms; Fennec; GreenPower; Hut 8; Restaurant Brands; Sigma Lithium; Solaris	02/07
Fennec Pharmaceuticals Inc. Announces Executive Changes	01/07
Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue	14/05
Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	23/04
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	19/04
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	17/04
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	06/04
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	04/04
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	21/03
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Sector Update: Health Care Stocks Steady Premarket Monday	18/03
Sector Update: Health Care	18/03
Fennec Pharmaceuticals Inc. and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	18/03
Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023	01/03
Fennec Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Issues Reminder of Non-Substitution of PEDMARK®? (Sodium Thiosulfate Injection) for Pediatric Patients Receiving Cisplatin	01/02
Wedbush Reviews Fennec Pharmaceuticals' Q3 Results	07/11
Fennec Pharmaceuticals Reports Pedmark Net Product Revenue of US$6.5 Million In Q3 2023	06/11
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	06/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Fennec Pharmaceuticals Inc. Toronto S.E.

Equities

FRX

CA31447P1009

Other languages

Filters